RxDoctor Payments Data

David Emmel, MD

Ophthalmology · Wethersfield, CTNPI 1225134208

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 31 payments — averaging $35.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$329
  • Alcon$309
  • Omeros Corporation$125
  • Sun Pharmaceutical Industries Inc.$112
  • Oyster Point Pharma, Inc.$66
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$48
  • plus $119 from 4 others

What the payments were for

  • Food & beverage$1,08398%
  • Education$252%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,108 in reported general payments places this provider in the 50th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$55,778
Medicare patients
310
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost155$109,898
RestasisCyclosporine42$64,490
Cyclosporine29$17,407
CombiganBrimonidine Tartrate/Timolol32$14,377
RhopressaNetarsudil Mesylate21$11,562
RocklatanNetarsudil Mesylat/Latanoprost16$10,160
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol37$6,159
VyzultaLatanoprostene Bunod12$6,044
SimbrinzaBrinzolamide/Brimonidine Tart20$5,861
ProlensaBromfenac Sodium14$4,970
BesivanceBesifloxacin Hcl19$4,242
Latanoprost349$4,038
Prednisolone Acetate69$3,909
Brimonidine Tartrate49$3,750
Travoprost22$2,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$329$188,765229 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Besivance$48$9,21233 claims
Bausch & Lomb Americas Inc.Vyzulta$45$6,04412 claims
AlconSimbrinza$309$5,86120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Wethersfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →